A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | MicrobiomeTrials← Back to trialsNCT06253130
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2023-12-11Est. Completion: 2027-06-01
Enrollment target: 156 participants Locations- The University of Arizona Cancer Center, Tucson, Arizona, United States
- University of Arkansas Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas, United States
- Hoag Health Center Irvine, Irvine, California, United States
- University California Irvine, Irvine, California, United States
- Sharp Memorial Hospital, San Diego, California, United States
- University of California San Francisco (UCSF), San Francisco, California, United States
- Sarah Cannon Research Institute Health One, Denver, Colorado, United States
- Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States
- Advent Health Research Institute, Celebration, Florida, United States
- Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
- Karmanos Cancer Institute, Detroit, Michigan, United States
- Henry Ford Health, Detroit, Michigan, United States
- University of Minnesota-Clinical Research Unit, Minneapolis, Minnesota, United States
- Washington University - Siteman Cancer Center, St Louis, Missouri, United States
Other microbiome trials you might be interested in
MelanomaAdvanced MelanomaMetastatic MelanomaUnresectable Melanoma
CMP-001-011 is a Phase 2/3 study of CMP-001 intratumoral (IT) and nivolumab intravenous (IV) compared to nivolumab monot…
Phoenix, United StatesCompleted Jul 22, 2024
Advanced Vaginal AdenocarcinomaAdvanced Vaginal Adenosquamous CarcinomaAdvanced Vaginal Squamous Cell CarcinomaCervical Adenocarcinoma
John Theurer Cancer Center, Hackensack, New Jersey, United StatesCayuga Medical Center, Ithaca, New York, United StatesLifespan Cancer Institute, Providence, Rhode Island, United StatesMedical University of South Carolina (MUSC) - Hollings CC, Charleston, South Carolina, United StatesWest Cancer Center & Research Institute, Germantown, Tennessee, United StatesSarah Cannon Research Institue Oncology, Nashville, Tennessee, United StatesSTART - South Texas Accelerated Research Therapeutics, San Antonio, Texas, United StatesSTART Mountain Region, West Valley City, Utah, United StatesScientia Clinical Research Ltd, Randwick, New South Wales, AustraliaMater Cancer Care Centre, Mater Misericordiae Limited, South Brisbane, Queensland, AustraliaGold Coast Private Hospital, Southport, Queensland, AustraliaMacquarie University, Sydney, Queensland, AustraliaPrincess Alexandra Hospital, Woolloongabba, Queensland, AustraliaPeninsula and south eastern haematology and oncology group, Frankston, Victoria, AustraliaCross Cancer Institute, Edmonton, Alberta, CanadaSunnybrook Research Institute, Toronto, Ontario, CanadaPrincess Margaret Cancer Centre-University Health Network, Toronto, Ontario, CanadaSun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaThe Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaShandong Cancer Hospital, Jinan, Shandong, ChinaSir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaChongqing University Cancer Hospital, Chongqing, ChinaFujian Cancer Hospital, Fuzhou, ChinaZhejiang Cancer Hospital, Hangzhou, ChinaFudan University Shanghai Cancer Center, Shanghai, ChinaRighospitalet, Copenhagen, DenmarkHospices Civils de Lyon - CHU Lyon Sud, Pierre-Bénite, Rhone, FranceCLCC François Baclesse, Caen, FranceInstitut Gustave Roussy, Villejuif, FranceCHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, South KoreaGachon University - Gil Medical Center, Incheon, Namdong-gu, South KoreaSeverance Hospital, Yonsei University Health System, Seoul, South KoreaHospital Universitari Parc Taulí, Sabadell, Barcelona, SpainHospital Clinico San Carlos, Madrid, Madrid, SpainClínica Universidad de Navarra - Hospital, Pamplona, Navarre, SpainHospital del Mar, Barcelona, SpainVall d'Hebron Institute of Oncology, Barcelona, SpainFundacion MD Anderson Cancer Center, Madrid, SpainSTART Madrid Fundación Jiménez Díaz, Madrid, SpainSTART-CIOCC HM Sanchinarro Hospital, Madrid, SpainUniversidad De Sevilla - Hospital Universitario Virgen Macarena, Seville, SpainHospital Clinico Universitario de Valencia - INCLIVA, Valencia, SpainCervical Adenosquamous Carcinoma
Cervical Squamous Cell Carcinoma
Stage IB2 Cervical Cancer AJCC v6 and v7
Stage II Cervical Cancer AJCC v7
Stage II Vaginal Cancer AJCC v6 and v7
Stage IIA Cervical Cancer AJCC v7
Stage IIB Cervical Cancer AJCC v6 and v7
Stage III Vaginal Cancer AJCC v6 and v7
Stage IIIB Cervical Cancer AJCC v6 and v7
Stage IV Vaginal Cancer AJCC v6 and v7
Stage IVA Cervical Cancer AJCC v6 and v7
Stage IVA Vaginal Cancer AJCC v6 and v7
Unresectable Vaginal Carcinoma
Vaginal Adenocarcinoma
Vaginal Adenosquamous Carcinoma
Vaginal Carcinoma
Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
This randomized phase III trial studies radiation therapy and cisplatin with triapine to see how well they work compared…
Birmingham, United StatesEst. completion Jan 26, 2023
Locally Advanced Pancreatic CarcinomaStage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Unresectable Pancreatic Carcinoma
This phase I trial tests the safety and tolerability of olaparib in combination with durvalumab and radiation therapy in…
Irvine, United StatesCompleted Jul 1, 2026